Investment
Features
FeesSafety
Academy
More
Pluang+

Oxford Square Capital struggles to cover dividends, risking further NAV decline and share price drop.

Analyst Insights
06 Oct 2026
Seeking Alpha
View Source
Bearish
Oxford Square Capital struggles to cover dividends, risking further NAV decline and share price drop.

Oxford Square Capital Corp. is rated Hold as it generates only 48% of the investment income needed to cover its dividends, leading to ongoing net asset value (NAV) declines and a 68% drop in share price over five years. Despite a strong balance sheet and good cash returns from collateralized loan obligations (CLOs), the NAV per share is expected to fall 18% by 2027, raising concerns about the sustainability of dividends. Management aims to grow through CLO equity investments, but risks from dividend coverage shortfalls and NAV erosion limit potential share price gains. Investors should be cautious about the company’s dividend sustainability and future performance.

Oxford Square Capital's dividend risk is the subject here. For readers following the Financials sector, Pluang data shows that out of 85 priced US Financials stocks, 70 rose and 10 fell today. Deutsche Bank AG was priced at USD 35.42 with a 1-day change of +1.29%, Banco Bilbao Vizcaya Argentaria SA at USD 27.28 with +1.26%, and Robinhood Markets, Inc. at USD 115.50 with +1.22%. This data is as of Oct 06, 2026 18:43 WIB.

More News

Costco shares drop 10% in 6 months while S&P 500 rises 17%, raising value questions below $900.

Costco shares drop 10% in 6 months while S&P 500 rises 17%, raising value questions below $900.

Over the past six months, Costco's stock has fallen by 10%, contrasting with the S&P 500's 17% gain. This decline has sparked debate on whether Costco's shares, now trading under $900, represent a buying opportunity. Investors are weighing if the pri...

Analyst Insights
Neutral
3 hours ago
OKYO Pharma starts Phase 3 trial for neuropathic corneal pain drug urcosimod

OKYO Pharma starts Phase 3 trial for neuropathic corneal pain drug urcosimod

OKYO Pharma has enrolled the first patients in its Phase 3 NEPTUNE trial testing urcosimod for neuropathic corneal pain, a severe eye condition with no FDA-approved treatment. The trial has begun in the US and will expand to Europe, with patients rec...

Market News
Bullish
4 hours ago
Wall Street agrees on 5 dividend stocks yielding 5%+ for reliable passive income.

Wall Street agrees on 5 dividend stocks yielding 5%+ for reliable passive income.

Wall Street analysts have reached a rare consensus on five dividend stocks yielding 5% or more, seen as strong buys for dependable passive income. These stocks—Amcor, Energy Transfer, International Paper, Mid-America Apartment Communities, and Verizo...

Analyst Insights
Bullish
4 hours ago
OKX secures $25B valuation in funding round with QRT, Circle, Ripple, and SC Ventures backing

OKX secures $25B valuation in funding round with QRT, Circle, Ripple, and SC Ventures backing

Crypto exchange OKX has maintained its $25 billion valuation in a new funding round featuring Qube Research & Technologies (QRT), Circle, Ripple, and Standard Chartered’s SC Ventures. The fresh capital will help OKX enhance its market infrastructure ...

Market News
Bullish
4 hours ago
Meta tests full-screen video-first Facebook app in India, focusing on Reels to boost video engagement.

Meta tests full-screen video-first Facebook app in India, focusing on Reels to boost video engagement.

Meta has started testing a new Facebook user experience in India that opens the app directly into full-screen video, highlighting Reels. This test aims to create a more immersive, video-centric experience and follows Meta's broader strategy to priori...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App